AdWorld Businesses for Sale
Visit World Businesses for Sale
Thinking of selling your business? Buy or sell a business locally, nationally or worldwide. 10% off with code AWN10.
Brain map plus magnets: the FDA-cleared MeRT treatment for PTSD (full trial data not yet published)
The full story behind my Short: The FDA has cleared Wave Neuroscience's MeRT System, which uses an EEG to personalise transcranial magnetic stimulation, as an add-on treatment for adults with PTSD. The company reports a 52% symptom reduction and 68% remission; the full trial data have not yet been published.
The short version
The FDA has cleared a PTSD treatment that maps your brain, then stimulates it with magnets. It's called MeRT (Magnetic EEG-guided Resonance Therapy), from Wave Neuroscience, tested with researchers at the Texas A&M Health Institute of Biosciences and Technology. An EEG records the brain's electrical activity, and an AI-assisted algorithm uses it to personalise transcranial magnetic stimulation (TMS). In the trial, people had five sessions a week for five to six weeks. The company reports that symptoms fell by 52% and that 68% of patients reached remission (in the FDA summary, remission was a post-hoc analysis: 68.2% of the active group). A 2020 review found remission rates of about 11% at most with PTSD drugs, but that is a different study, not a head-to-head comparison. The full trial results have not yet been published; the FDA's 510(k) summary describes 158 adults randomised to MeRT or sham treatment. It is cleared as an adjunct (add-on) to existing PTSD care, for adults; access and insurance coverage are the next hurdles (FDA K260402; Texas A&M, 2026).
FDA-cleared3 June 2026 (510(k) K260402), as an adjunct treatment for adult PTSD [2]
158adults in the randomised, double-blind, sham-controlled pivotal trial (77 active, 81 sham) [2]
52% / 68%symptom reduction / remission, company-reported; remission was a post-hoc analysis [1][2]
Not yet publishedthe full trial findings are still being prepared for public release [1]
What they found
MeRT (Magnetic EEG-guided Resonance Therapy) was developed by Wave Neuroscience, a California company, and tested in collaboration with the research team of Kenneth S. Ramos, MD, PhD, at the Texas A&M Health Institute of Biosciences and Technology. It combines an electroencephalogram (EEG), which records the brain's electrical activity, with transcranial magnetic stimulation (TMS), which delivers magnetic pulses through a coil on the scalp. An AI-assisted algorithm uses each person's EEG to personalise the stimulation; the FDA summary describes the stimulation frequency being set within 8–13 Hz from the patient's EEG [1][2].
The FDA's 510(k) summary describes a multi-site, double-blind, randomised, sham-controlled pivotal trial. The intention-to-treat population was 158 participants, 77 assigned to active treatment and 81 to sham, with 20–25 sessions; 84% completed treatment. PTSD symptom severity improved significantly more with active treatment than with sham on both the PCL-5 and the CAPS-5 scales. In a post-hoc analysis, 68.2% of the active group met criteria for remission at follow-up [2]. Texas A&M's release says participants had five sessions a week for five to six weeks, and quotes Wave's chief medical officer, Erik Won, MD, reporting a 52% reduction in symptoms [1].
The full findings are “being processed for public dissemination”, so independent researchers cannot yet check them [1]. The release compares the result with a 2020 review of PTSD medications that found remission rates of 10.9% at most; that is a different study in different patients, not a head-to-head comparison [1]. MeRT received FDA Breakthrough Device designation in 2024 [1][3].
Watch the Short
AI voice note: the narration in this Short is my own voice, cloned with AI.
About this page
The 52% symptom reduction is company-reported (Wave Neuroscience's chief medical officer, quoted in Texas A&M's release); I could not find it in an independent publication. The 68% remission figure matches the FDA 510(k) summary (68.2% of the active group), where it is described as a post-hoc analysis. The full trial data have not yet been published. The ~11% drug figure comes from a separate 2020 review, so it is not a head-to-head comparison. The device is cleared as an adjunct treatment for adults. All photos are illustrative, from Wikimedia Commons (credited below).
Why it matters
- Few options. Only two drugs are FDA-approved for PTSD, both antidepressants (SSRIs), and many people don't reach remission on them [1].
- Personalised. Ramos compares symptom-masking drugs to putting a tarp on a damaged roof, and MeRT to replacing the shingles [1].
- Next steps. It is an add-on treatment, not a replacement, and the team is working on wider access and insurance coverage [1].
Full narration (transcript)
The FDA just cleared a PTSD treatment that maps your brain, then stimulates it with magnets. It's called MeRT, made by Wave Neuroscience and tested with Texas A&M. First, an EEG records your brain's electrical rhythm, like a personal brain map. Then an AI-assisted algorithm personalises magnetic stimulation, called TMS, to match it. In the trial, people had five sessions a week, for five to six weeks. The company reports symptoms fell by 52 percent, and 68 percent of patients reached remission. But here's where it gets interesting. A 2020 review found PTSD drugs bring remission to about 11 percent at most. That's a different study, so it's not a head-to-head comparison. The full trial data hasn't been published yet. The FDA summary describes 158 adults, tested against a sham. It's cleared as an add-on to existing PTSD care, and insurance cover is the next hurdle. The researchers say it's the first non-drug treatment cleared specifically for PTSD. Follow the link to the main website for much deeper information.
Sources
- [1] Texas A&M University (2026). “Breakthrough PTSD treatment achieves 68% remission rate in clinical trial.” ScienceDaily, 23 October 2026 (from Texas A&M Health, “New FDA clearance gives PTSD patients more precise, effective treatment options”, Vital Record, 19 August 2026). sciencedaily.com
- [2] U.S. Food and Drug Administration (2026). 510(k) K260402, MeRT System (Wave Neuroscience): clearance letter and 510(k) summary, decision date 3 June 2026. Clinical trial NCT02990793. accessdata.fda.gov
- [3] Texas A&M Institute of Biosciences and Technology (2026). “Texas A&M Health and Wave Neuroscience Announce FDA Clearance of MeRT for PTSD.” ibt.tamu.edu
Credits
Images via Wikimedia Commons (illustrative): PTSD - Taking Care of the Invisible Wounds 161202-A-EP957-027.jpg (Sgt. 1st Class Shelman Spencer, Public domain); Texas A&M Health Science Center.jpg (Texas A&M Health Science Center, CC BY-SA 4.0); EEG Recording Cap.jpg (Chris Hope, CC BY 2.0); Transcranial magnetic stimulation.jpg (Eric Wassermann, M.D., Public domain); Man’s best friend helps NC Guardsman with PTSD (Image 1 of 8) (12002105586).jpg (DVIDSHUB, CC BY 2.0). Sketches and animation: my own. Narration: AI clone of Nasper Mushonga's own voice (Chatterbox TTS by Resemble AI, MIT licence), used with his consent.